RESPONSE PENDING: Your Meeting with Tanushree Banerjee Tomorrow...
Here is the latest financial fact sheet of GLENMARK LIFE SCIENCES. For more details, see the GLENMARK LIFE SCIENCES quarterly results and GLENMARK LIFE SCIENCES share price. For a sector overview, read our pharmaceuticals sector report.
1 Day | % | 0.3 |
No. of shares | m | 122.53 |
1 Week | % | 1.7 |
1 Month | % | 7.6 |
1 Year | % | 75.9 |
52 week H/L | Rs | 904.2/464.1 |
No. of Mths Year Ending |
12 Mar-19* |
12 Mar-20* |
12 Mar-21* |
12 Mar-22* |
12 Mar-23* |
5-Yr Chart Click to enlarge
|
---|
GLENMARK LIFE SCIENCES EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | NA | NA | NA | 800 | 534 | |
Low | Rs | NA | NA | NA | 376 | 369 | |
Sales per share (Unadj.) | Rs | 4,522.6 | 7,843.4 | 1,923.6 | 173.3 | 176.4 | |
Earnings per share (Unadj.) | Rs | 997.9 | 1,597.4 | 358.8 | 34.2 | 38.1 | |
Diluted earnings per share | Rs | 16.0 | 25.6 | 28.7 | 34.2 | 38.1 | |
Cash flow per share (Unadj.) | Rs | 1,096.2 | 1,747.3 | 392.8 | 37.3 | 41.5 | |
Dividends per share (Unadj.) | Rs | 0 | 0 | 0 | 21.00 | 21.00 | |
Adj. dividends per share | Rs | 0.00 | 0.00 | 0.00 | 21.00 | 21.00 | |
Avg Dividend yield | % | 0 | 0 | 0 | 3.6 | 4.7 | |
Book value per share (Unadj.) | Rs | 449.6 | 2,049.4 | 768.1 | 167.4 | 174.0 | |
Adj. book value per share | Rs | 7.2 | 32.8 | 61.4 | 167.4 | 174.0 | |
Shares outstanding (eoy) | m | 1.96 | 1.96 | 9.80 | 122.53 | 122.53 | |
Price / Sales ratio | x | 0 | 0 | 0 | 3.4 | 2.6 | |
Avg P/E ratio | x | 0 | 0 | 0 | 17.2 | 11.8 | |
P/CF ratio (eoy) | x | 0 | 0 | 0 | 15.8 | 10.9 | |
Price / Book Value ratio | x | 0 | 0 | 0 | 3.5 | 2.6 | |
Dividend payout | % | 0 | 0 | 0 | 61.5 | 55.1 | |
Avg Mkt Cap | Rs m | 0 | 0 | 0 | 72,043 | 55,321 | |
Total wages/salary | Rs m | 1,063 | 1,423 | 1,491 | 1,687 | 1,802 |
GLENMARK LIFE SCIENCES INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 8,864 | 15,373 | 18,852 | 21,232 | 21,612 | |
Other income | Rs m | 10 | 120 | 8 | 147 | 290 | |
Total revenues | Rs m | 8,874 | 15,493 | 18,860 | 21,379 | 21,902 | |
Gross profit | Rs m | 2,472 | 4,720 | 5,911 | 6,161 | 6,423 | |
Depreciation | Rs m | 193 | 294 | 334 | 379 | 421 | |
Interest | Rs m | 6 | 335 | 875 | 280 | 5 | |
Profit before tax | Rs m | 2,283 | 4,211 | 4,709 | 5,649 | 6,286 | |
Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Tax | Rs m | 327 | 1,080 | 1,194 | 1,462 | 1,616 | |
Profit after tax | Rs m | 1,956 | 3,131 | 3,516 | 4,187 | 4,670 | |
Gross profit margin | % | 27.9 | 30.7 | 31.4 | 29.0 | 29.7 | |
Effective tax rate | % | 14.3 | 25.6 | 25.3 | 25.9 | 25.7 | |
Net profit margin | % | 22.1 | 20.4 | 18.6 | 19.7 | 21.6 |
GLENMARK LIFE SCIENCES BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 9,307 | 11,601 | 16,225 | 21,274 | 23,687 | |
Current liabilities | Rs m | 13,804 | 13,075 | 14,449 | 7,468 | 10,228 | |
Net working cap to sales | % | -50.7 | -9.6 | 9.4 | 65.0 | 62.3 | |
Current ratio | x | 0.7 | 0.9 | 1.1 | 2.8 | 2.3 | |
Inventory Days | Days | 3 | 2 | 2 | 3 | 2 | |
Debtors Days | Days | 185 | 152 | 120 | 116 | 136 | |
Net fixed assets | Rs m | 5,447 | 5,655 | 5,980 | 7,064 | 8,518 | |
Share capital | Rs m | 20 | 20 | 20 | 245 | 245 | |
"Free" reserves | Rs m | 862 | 3,997 | 7,508 | 20,263 | 21,070 | |
Net worth | Rs m | 881 | 4,017 | 7,527 | 20,508 | 21,315 | |
Long term debt | Rs m | 0 | 0 | 0 | 0 | 0 | |
Total assets | Rs m | 14,754 | 17,256 | 22,206 | 28,338 | 32,205 | |
Interest coverage | x | 378.4 | 13.6 | 6.4 | 21.2 | 1,150.2 | |
Debt to equity ratio | x | 0 | 0 | 0 | 0 | 0 | |
Sales to assets ratio | x | 0.6 | 0.9 | 0.8 | 0.7 | 0.7 | |
Return on assets | % | 13.3 | 20.1 | 19.8 | 15.8 | 14.5 | |
Return on equity | % | 221.9 | 77.9 | 46.7 | 20.4 | 21.9 | |
Return on capital | % | 259.7 | 113.2 | 74.2 | 28.9 | 29.5 | |
Exports to sales | % | 0 | 0 | 0 | 0 | 0 | |
Imports to sales | % | 0 | 0 | 0 | 0 | 0 | |
Exports (fob) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Imports (cif) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Fx inflow | Rs m | 72 | 6,266 | 7,870 | 10,568 | 9,691 | |
Fx outflow | Rs m | 39 | 2,924 | 3,955 | 3,883 | 5,001 | |
Net fx | Rs m | 34 | 3,342 | 3,915 | 6,685 | 4,689 |
GLENMARK LIFE SCIENCES CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | 104 | 1,950 | 3,881 | 5,976 | 3,134 | |
From Investments | Rs m | -89 | -505 | -687 | -1,222 | -1,541 | |
From Financial Activity | Rs m | 5 | -1,366 | -2,138 | -788 | -3,876 | |
Net Cashflow | Rs m | 21 | 79 | 1,056 | 3,966 | -2,283 |
Share Holding
Shareholding as on Mar 2024
|
Company Information
|
CHM: Glenn Saldanha | COMP SEC: Rudalf Corriea | YEAR OF INC: 2011 | BSE CODE: 543322 | FV (Rs): 2 | DIV YIELD (%): 2.6 |
Read: GLENMARK LIFE SCIENCES 2022-23 Annual Report Analysis
More Pharmaceuticals Company Fact Sheets: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
Compare GLENMARK LIFE SCIENCES With: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
After opening the day on positive note, Indian share markets continued the momentum as the session progressed and ended on firm footing.